1. Home
  2. PLBY vs MDWD Comparison

PLBY vs MDWD Comparison

Compare PLBY & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.84

Market Cap

232.8M

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.74

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
MDWD
Founded
1953
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.8M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
PLBY
MDWD
Price
$1.84
$18.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.00
$37.50
AVG Volume (30 Days)
1.3M
82.4K
Earning Date
11-12-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,510,000.00
$20,932,000.00
Revenue This Year
$4.97
$15.89
Revenue Next Year
$8.38
$25.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.15
52 Week Low
$0.90
$14.14
52 Week High
$2.53
$22.51

Technical Indicators

Market Signals
Indicator
PLBY
MDWD
Relative Strength Index (RSI) 50.06 53.42
Support Level $1.70 $18.55
Resistance Level $1.93 $18.96
Average True Range (ATR) 0.15 0.53
MACD -0.03 -0.00
Stochastic Oscillator 16.27 27.38

Price Performance

Historical Comparison
PLBY
MDWD

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: